苏格兰12-13岁接种二价HPV疫苗后20岁宫颈疾病患病率:回顾性人群研究
该回顾性人群研究纳入苏格兰1988至1996年出生、20岁时有涂片结果的138 692名女性,评估12-13岁接种二价HPV疫苗对20岁宫颈疾病的影响。与未接种女性相比,1995和1996年出生接种女性CIN3+、CIN2+和CIN1患病率分别降低89%、88%和79%,且接种年龄越小效果越好,未接种女性中也观察到群体保护。
要点
- 12-13岁接种二价HPV疫苗使20岁时CIN3+患病率降低89%。
- 接种年龄越小疫苗效果越好,12-13岁接种对CIN3+效果为86%。
- 未接种女性中观察到针对高级别宫颈疾病的群体保护。
核心结论
- 苏格兰12-13岁女孩常规接种二价HPV疫苗显著降低20岁时浸润前宫颈疾病患病率。
- 未接种女性中可见具有临床意义的群体保护。
- 二价疫苗被证实高效,应大幅降低宫颈癌发病率。
研究设计与样本
- 回顾性人群研究,纳入1988年1月1日至1996年6月5日出生、20岁时有涂片结果的138 692名女性。
- 设置于苏格兰国家疫苗接种和宫颈筛查规划。
- 使用逻辑回归计算疫苗接种对筛查第一年细胞学结果及相关组织学诊断的影响。
主要发现
- 与1988年出生未接种女性相比,1995和1996年出生接种女性CIN3+患病率降低89%(95%CI 81%至94%),从0.59%(0.48%至0.71%)降至0.06%(0.04%至0.11%)。
- CIN2+患病率降低88%(95%CI 83%至92%),从1.44%(1.28%至1.63%)降至0.17%(0.12%至0.24%)。
- CIN1患病率降低79%(95%CI 69%至86%),从0.69%(0.58%至0.63%)降至0.15%(0.10%至0.21%)。
- 12-13岁接种女性CIN3+疫苗效果为86%(95%CI 75%至92%),17岁接种为51%(95%CI 28%至66%)。
- 1995和1996年出生未接种女孩中观察到针对高级别宫颈疾病的群体保护证据。
关键数值与推荐
- CIN3+患病率从0.59%(0.48%至0.71%)降至0.06%(0.04%至0.11%),降低89%(95%CI 81%至94%)。
- CIN2+患病率从1.44%(1.28%至1.63%)降至0.17%(0.12%至0.24%),降低88%(95%CI 83%至92%)。
- CIN1患病率从0.69%(0.58%至0.63%)降至0.15%(0.10%至0.21%),降低79%(95%CI 69%至86%)。
- 12-13岁接种对CIN3+效果86%(95%CI 75%至92%),17岁接种51%(95%CI 28%至66%)。
临床怎么用
- 全科医生应依据研究证据推荐12-13岁女孩常规接种二价HPV疫苗以预防宫颈疾病。
- 向家长和适龄女孩说明早接种对高级别宫颈病变保护效果更佳。
- 在宫颈癌预防规划中考虑二价HPV疫苗的群体保护效应。
局限性
- 研究为回顾性设计,可能受混杂因素影响。
- 仅报告20岁筛查第一年数据,长期效果需进一步随访。
- 结果基于苏格兰人群,外推至其他地区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify the effect on cervical disease at age 20 years of immunisation with bivalent human papillomavirus (HPV) vaccine at age 12-13 years. DESIGN: Retrospective population study, 1988-96. SETTING: National vaccination and cervical screening programmes in Scotland. PARTICIPANTS: 138 692 women born between 1 January 1988 and 5 June 1996 and who had a smear test result recorded at age 20. MAIN OUTCOME MEASURES: Effect of vaccination on cytology results and associated histological diagnoses from first year of screening (while aged 20), calculated using logistic regression. RESULTS: 138 692 records were retrieved. Compared with unvaccinated women born in 1988, vaccinated women born in 1995 and 1996 showed an 89% reduction (95% confidence interval 81% to 94%) in prevalent cervical intraepithelial neoplasia (CIN) grade 3 or worse (from 0.59% (0.48% to 0.71%) to 0.06% (0.04% to 0.11%)), an 88% reduction (83% to 92%) in CIN grade 2 or worse (from 1.44% (1.28% to 1.63%) to 0.17% (0.12% to 0.24%)), and a 79% reduction (69% to 86%) in CIN grade 1 (from 0.69% (0.58% to 0.63%) to 0.15% (0.10% to 0.21%)). Younger age at immunisation was associated with increasing vaccine effectiveness: 86% (75% to 92%) for CIN grade 3 or worse for women vaccinated at age 12-13 compared with 51% (28% to 66%) for women vaccinated at age 17. Evidence of herd protection against high grade cervical disease was found in unvaccinated girls in the 1995 and 1996 cohorts. CONCLUSIONS: Routine vaccination of girls aged 12-13 years with the bivalent HPV vaccine in Scotland has led to a dramatic reduction in preinvasive cervical disease. Evidence of clinically relevant herd protection is apparent in unvaccinated women. These data are consistent with the reduced prevalence of high risk HPV in Scotland. The bivalent vaccine is confirmed as being highly effective vaccine and should greatly reduce the incidence of cervical cancer. The findings will need to be considered by cervical cancer prevention programmes worldwide.
引用
- Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019. PMID: 30944092. doi:10.1136/bmj.l1161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。